Auto-Injector Devices
•10 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (10)
%
| Company | Market Cap | Price |
|---|---|---|
|
BD Libertas and BD Evolve auto-injector platforms enable at-home biologic drug administration.
|
$53.47B |
$186.56
-1.50%
|
|
Auto-Injector Devices reflect JBL's healthcare device manufacturing capabilities tied to at-home therapies.
|
$20.82B |
$193.99
-5.75%
|
|
West's GLP-1 self-injection device platforms (Auto-Injector Devices) are a core product line.
|
$18.81B |
$261.77
-1.19%
|
|
Halozyme is developing and commercializing auto-injector technologies to support at-home administration of injectable therapies.
|
$7.90B |
$64.10
-2.20%
|
|
The company is expanding into auto-injector devices for patient self-administration.
|
$7.22B |
$23.85
-0.58%
|
|
VRDN-003 strategy includes subcutaneous administration via auto-injector, i.e., Auto-Injector Devices.
|
$1.71B |
$20.99
-3.94%
|
|
KE's capabilities include auto-injector device manufacturing for drug-device combinations.
|
$729.22M |
$29.91
+1.08%
|
|
Autoinjector devices are a core planned delivery system for SCPH's at‑home administration of FUROSCIX.
|
$299.33M |
$5.67
|
|
Otrexup is an auto-injector device for delivering therapy, signaling the Auto-Injector Devices category.
|
$79.98M |
$0.83
-4.47%
|
|
SCN-104 is an injection pen (drug-delivery device), aligning with Auto-Injector Devices.
|
$9.20M |
$0.70
-6.52%
|
Loading industry metrics...
Loading comparison data...
